Results 181 to 190 of about 123,600 (352)

Very-low-dose decitabine and rhTPO for thrombocytopenia in lower-risk myelodysplastic syndrome. [PDF]

open access: yesAnn Hematol
Gao Z   +17 more
europepmc   +1 more source

[Risk factors for leukemia transformation in patients with myelodysplastic syndromes].

open access: green, 2022
Songyang Zhao   +11 more
openalex   +2 more sources

Clinical, Genetic, and Pathologic Variability in Myelodysplastic Syndromes and Precursor Conditions Across Race, Ethnicity, and Sex

open access: yesAmerican Journal of Hematology, Volume 101, Issue 6, Page 1407-1420, June 2026.
ABSTRACT The epidemiology of myelodysplastic syndromes/neoplasms (MDS) is challenging to define due to inconsistent reporting, complex diagnostic procedures, and evolving diagnostic criteria. Using the National MDS Natural History Study—a prospective cohort with centrally adjudicated histopathology and genetic variant review—we characterized the ...
Nancy Gillis   +25 more
wiley   +1 more source

A phase II trial of ruxolitinib in combination with azacytidine in myelodysplastic syndrome/myeloproliferative neoplasms [PDF]

open access: bronze, 2017
Rita Assi   +22 more
openalex   +1 more source

Successful Treatment of Recurrent Hematometra With Ethanol Sclerotherapy: A Case Report

open access: yesClinical Case Reports, Volume 14, Issue 6, June 2026.
ABSTRACT To our knowledge, this case report is the first to show that ethanol sclerotherapy can safely and effectively resolve recurrent hematometra caused by postradiotherapy stenosis and recurrent cervical cancer. For patients with poor overall condition in whom cervical drainage is not feasible, this minimally invasive approach may serve as a ...
Kojiro Tanabe   +3 more
wiley   +1 more source

Home - About - Disclaimer - Privacy